-
1
-
2
-
3
-
4
-
5
Mitochondria-Targeted Antioxidants as a Therapeutic Strategy for Chronic Obstructive Pulmonary Disease
Published 2023-04-01Get full text
Article -
6
-
7
The burden of splice-disrupting variants in inherited heart disease and unexplained sudden cardiac death
Published 2023-10-01Get full text
Article -
8
The Tumour Vasculature as a Target to Modulate Leucocyte Trafficking
Published 2021-04-01Get full text
Article -
9
-
10
Nicotinamide Inhibits T Cell Exhaustion and Increases Differentiation of CD8 Effector T Cells
Published 2022-01-01Get full text
Article -
11
-
12
Exploring Viral–Host Protein Interactions as Antiviral Therapies: A Computational Perspective
Published 2024-03-01Get full text
Article -
13
A single dose, BCG-adjuvanted COVID-19 vaccine provides sterilising immunity against SARS-CoV-2 infection
Published 2021-11-01Get full text
Article -
14
A hepatic network of dendritic cells mediates CD4 T cell help outside lymphoid organs
Published 2024-02-01Get full text
Article -
15
A Novel Function of Sphingosine Kinase 2 in the Metabolism of Sphinga-4,14-Diene Lipids
Published 2020-06-01Get full text
Article -
16
Generation of an induced pluripotent stem cell line from a hypertrophic cardiomyopathy patient with a pathogenic myosin binding protein C (MYBPC3) p.Arg502Trp mutation
Published 2018-12-01“…This line is a useful resource for studying and modeling hypertrophic cardiomyopathy.Resource tableUnlabelled TableUnique stem cell line identifierMCCI0003i-HCMAlternative name(s) of stem cell lineIK1InstitutionCentenary InstituteContact information of distributorChristopher Semsarian; c.semsarian@centenary.org.auType of cell lineiPSCOriginHumanAdditional origin infoAge: 58Sex: maleEthnicity: North-west EuropeanCell sourcePeripheral blood mononuclear cellsClonalityClonalMethod of reprogrammingTransgene free (episomal vectors)Genetic modificationNAType of modificationNAAssociated diseaseHypertrophic CardiomyopathyGene/locusMYBPC3 c.1504C > T p.Arg502Trp, Chr11: 47364249 (on Assembly GRCh37)Method of modificationNAName of transgene or resistanceNAInducible/constitutive systemNADate archived/stock date2017Cell line repository/bankNAEthical approvalPatient informed consent obtained, and ethics review board-competent authority approval obtained through the Ethics Review Committee, Sydney Local Health District.Protocol No X13-0069 and HREC/13/RPAH/93…”
Get full text
Article -
17
Towards resolution of the intron retention paradox in breast cancer
Published 2022-12-01Get full text
Article -
18
-
19
-
20
Widespread Aberrant Alternative Splicing despite Molecular Remission in Chronic Myeloid Leukaemia Patients
Published 2020-12-01Get full text
Article